Top healthtech investors writing checks for Manchester startups in 2026

Manchester sits at the centre of a £120bn UK life sciences market. These 15 investors are actively backing Manchester healthtech founders in 2026.

Greater Manchester has a devolved health budget and one of the UK's largest NHS populations. That makes it a test bed investors can't ignore.

PXN Ventures runs a dedicated £20M GMC Life Sciences Fund. Northern Gritstone closed £20M additional capital for life sciences in April 2026.

You do not need to move to London to raise a serious healthtech round. The capital and the clinical partners are both here.

Set up an Ellty data room with your clinical evidence and NHS pilot data. Manchester healthtech investors check outcomes before they take a call.

What is a Manchester healthtech investor?

A Manchester healthtech investor backs companies building health technology in the North. That covers digital health, medtech, diagnostics, AI in healthcare, and clinical software.

Some are life sciences-dedicated funds. Others are generalist Northern funds with a health and deep tech thesis.

Manchester's edge is its NHS access. The region has a devolved health budget and over 3 million patients, letting founders run real-world trials that London rarely offers at the same scale.

Most want clinical validation, a named NHS or private healthcare partner, and a regulatory path. Compare London healthtech investors for growth rounds heading south.

15 Manchester healthtech investors

1. GMC Life Sciences Fund (PXN Ventures)

The Greater Manchester and Cheshire Life Sciences Fund is managed by PXN Ventures with backing from GMCA and Bruntwood SciTech. It backs biotech, medtech, and digital health with up to £2M per investment. CareLoop closed £1.8M from this fund to tackle severe mental illness, and SISU Health received investment in April 2025.

• Recent Deals: CareLoop £1.8M (2025); SISU Health (Apr 2025); up to £2M per deal; biotech, medtech, digital health mandate; Greater Manchester focus
• LinkedIn: PXN Ventures LinkedIn
• Sector Focus: Biotech, medtech, digital health
• Stage Focus: Seed to Series A
• Location: Manchester, UK
• Website: pxnventures.co.uk/gmc

2. Northern Gritstone

Northern Gritstone backs spinouts from the Universities of Manchester, Leeds, and Sheffield. They completed 24 investments in 2025 and closed £20M additional capital in April 2026, bringing total permanent capital to £382M. They invested in Manchester spinout Apini, a drug discovery company for chronic inflammatory diseases.

Use Ellty to share your clinical study data and IP documentation. University spinout funds check IP ownership before anything else.

• Recent Deals: Apini Manchester spinout investment; £20M rolling close (Apr 2026); 24 investments in 2025; £1M-£10M checks; life sciences and deep tech mandate
• LinkedIn: Northern Gritstone LinkedIn
• Sector Focus: Life sciences, healthtech, deep tech
• Stage Focus: Pre-seed to Series B
• Location: Manchester, UK
• Website: northerngritstone.com

3. Mercia Ventures

Mercia Ventures backed Semble's £30M Series C in June 2026 and Semble's £15M Series B in 2024. They back healthtech and digital health across the UK with their Connected Capital model. They suit Manchester founders raising a substantial healthtech round with real revenue.

• Recent Deals: Semble £30M Series C participant (Jun 2026); Semble £15M Series B (2024); £500K-£10M checks; healthtech and digital health mandate; UK-wide deal flow
• LinkedIn: Mercia Ventures LinkedIn
• Sector Focus: Healthtech, SaaS, digital health
• Stage Focus: Seed to Series C
• Location: Manchester and UK regions
• Website: mercia.co.uk

4. Octopus Ventures

Octopus Ventures backed Semble's £30M Series C in June 2026. They deploy £200M+ per year across health, consumer, and deep tech. They suit Manchester founders building healthtech platforms with real clinical adoption and growth-stage revenue.

• Recent Deals: Semble £30M Series C participant (Jun 2026); 18 investments in 2025; £1M-£20M checks; health and consumer mandate; UK and European deal flow
• LinkedIn: Octopus Ventures LinkedIn
• Sector Focus: Healthtech, deep tech, SaaS
• Stage Focus: Seed to Series C
• Location: London with Northern deal flow
• Website: octopusventures.com

5. BGF

BGF is the UK's most active growth investor and backs healthtech and medtech companies across the North. They led a Series A in a Northern university semiconductor spinout in 2025. They write £2M to £15M into companies with real revenue and a clear growth path.

Set up an Ellty data room with your revenue cohorts and clinical outcomes. BGF reviews management accounts in detail before any term sheet.

• Recent Deals: Northern university spinout Series A lead (2025); £2M-£15M checks; healthtech and medtech mandate; Series A to growth focus; UK regional deal flow
• LinkedIn: BGF LinkedIn
• Sector Focus: Healthtech, medtech, regional growth
• Stage Focus: Series A to growth
• Location: Manchester and UK-wide
• Website: bgf.co.uk

6. Bruntwood SciTech

Bruntwood SciTech is a Manchester science and innovation property company that co-manages the GMC Life Sciences Fund with PXN. They provide physical space, networks, and co-investment for healthtech founders in Manchester. They suit founders who want a Manchester base alongside their funding.

• Recent Deals: GMC Fund co-manager; CareLoop and SISU Health co-investment; Manchester Science Partnerships network; seed to Series A mandate; Manchester-based founders
• LinkedIn: Bruntwood SciTech LinkedIn
• Sector Focus: Life sciences, biotech, digital health
• Stage Focus: Seed to Series A
• Location: Manchester, UK
• Website: bruntwood.co.uk/scitech

7. PXN Ventures

PXN Ventures is Manchester's largest early-stage VC with £670M under management. Beyond the GMC Fund, they back healthtech broadly across the Northern portfolio. Their PraeSeed programme has invested in health and compliance startups in 2025 and 2026.

Read investor relations basics to prepare what PXN looks for in your fundraising update. Their 'more than money' model means they check in quarterly.

• Recent Deals: GMC Fund management; CareLoop £1.8M; SISU Health; PraeSeed programme; £200K-£8M checks; Northern healthtech mandate
• LinkedIn: PXN Ventures LinkedIn
• Sector Focus: Healthtech, SaaS, deep tech
• Stage Focus: Seed to Series A
• Location: Manchester, UK
• Website: pxnventures.co.uk

8. Parkwalk Advisors

Parkwalk Advisors launched the Northern Universities Venture Fund with Northern Gritstone in June 2025. They invest in university spinouts from Manchester, Leeds, and Sheffield. They suit founders with university IP looking to commercialise life sciences and healthtech.

• Recent Deals: Northern Universities Venture Fund launch (Jun 2025); university spinout mandate; £500K-£5M checks; life sciences and healthtech focus; Northern deal flow
• LinkedIn: Parkwalk Advisors LinkedIn
• Sector Focus: Life sciences, university spinouts, healthtech
• Stage Focus: Seed to Series A
• Location: London and Northern coverage
• Website: parkwalkadvisors.com

9. IQ Capital

IQ Capital backs deep tech and life sciences with a track record in university spinouts. They co-invested in Imperagen's £5M Manchester AI round in May 2026. Their life sciences thesis fits Manchester founders building at the intersection of AI and biotech.

• Recent Deals: Imperagen £5M round participant (May 2026); life sciences and deep tech mandate; £500K-£10M checks; seed to Series B focus; UK-wide deal flow
• LinkedIn: IQ Capital LinkedIn
• Sector Focus: Life sciences, biotech, deep tech
• Stage Focus: Seed to Series B
• Location: Cambridge with Northern deal flow
• Website: iqcapital.vc

10. NPIF II Praetura Equity Finance

NPIF II Praetura Equity Finance is the British Business Bank fund managed by PXN. They co-invest on Northern healthtech rounds and participated in the Manchester GMC Fund structure. They write £100K to £5M into Northern founders with a regional mandate.

Use Ellty to prepare a clear use-of-funds breakdown for NPIF II. Public fund managers require this before any investment committee meeting.

• Recent Deals: GMC Fund participant; Northern healthtech co-investment; £100K-£5M checks; regional mandate; BBB fund structure
• LinkedIn: Praetura Ventures LinkedIn
• Sector Focus: Healthtech, Northern tech, life sciences
• Stage Focus: Seed to Series A
• Location: Manchester, UK
• Website: pxnventures.co.uk

11. GC Angels

GC Angels is The Growth Company's venture arm in Greater Manchester. They back pre-seed and seed healthtech founders across the North. They prioritise underrepresented founders and companies with NHS pathway potential.

• Recent Deals: Venture Forward accelerator cohorts; pre-seed healthtech investments; £100K-£2M checks; underrepresented founder focus; Greater Manchester mandate
• LinkedIn: GC Angels LinkedIn
• Sector Focus: Healthtech, SaaS, regional tech
• Stage Focus: Pre-seed to seed
• Location: Manchester, UK
• Website: gcangels.uk

12. Committed Capital

Committed Capital led Healthera's Series A to £5.6M in April 2025. Healthera is a digital pharmacy and health services platform. They back digital health companies with NHS traction and real user growth from seed to Series A.

Read due diligence basics to prepare for what Committed Capital checks. Share your NHS validation data via Ellty to speed up the process.

• Recent Deals: Healthera £2M strategic investment (Apr 2025) boosting Series A to £5.6M; NHS traction mandate; £500K-£5M checks; digital health and SaaS focus; UK deal flow
• LinkedIn: Committed Capital LinkedIn
• Sector Focus: Digital health, healthtech, SaaS
• Stage Focus: Seed to Series A
• Location: UK-wide with Northern deal flow
• Website: committedcapital.com

13. Deepbridge Capital

Deepbridge Capital is a Northern EIS fund backing early-stage healthtech and life sciences founders. They write £250K to £3M using tax-efficient EIS structures. They suit Manchester healthtech founders raising a first institutional round with capital-efficient teams.

• Recent Deals: Northern EIS mandate; £250K-£3M checks; healthtech and life sciences focus; SEIS/EIS structures; seed to Series A stage
• LinkedIn: Deepbridge Capital LinkedIn
• Sector Focus: Healthtech, EIS, life sciences
• Stage Focus: Seed to Series A
• Location: North West, UK
• Website: deepbridgecapital.com

14. Foresight Group

Foresight Group backs Northern healthtech and SaaS from its regional funds. They co-invest on rounds alongside NPIF and PXN and write £1M to £5M into capital-efficient companies. They suit Manchester healthtech founders with recurring revenue looking for patient capital.

• Recent Deals: Northern healthtech co-investment mandate; £1M-£5M checks; SaaS and healthtech focus; seed to growth stage; UK regional deal flow
• LinkedIn: Foresight Group LinkedIn
• Sector Focus: Healthtech, SaaS, regional tech
• Stage Focus: Seed to growth
• Location: Manchester and UK regions
• Website: foresight.group

15. Maven Capital Partners

Maven Capital Partners runs Northern Powerhouse funds and backs healthtech alongside SaaS in the North. They write £1M to £5M into capital-efficient companies with clear revenue traction. They suit Manchester healthtech founders at seed or Series A.

Use Ellty to control who views sensitive patient data in your data room. Investors need outcomes data but should not download raw patient records.

• Recent Deals: Northern Powerhouse fund mandate; £1M-£5M checks; healthtech and Northern tech focus; seed to growth stage; UK regional deal flow
• LinkedIn: Maven Capital Partners LinkedIn
• Sector Focus: Healthtech, SaaS, Northern tech
• Stage Focus: Seed to growth
• Location: Manchester, UK
• Website: mavencp.com

How to get NHS validation in Manchester

Manchester's devolved health system runs through Greater Manchester Integrated Care. Getting a named NHS trust or GP network on board is the fastest signal for investors.

Health Innovation Manchester runs programmes to connect founders with NHS clinical teams. An NHS pilot that shows patient outcomes data is worth more than any pitch deck in 2026.

Read North West England investors for a broader view of capital available across the region, not just Manchester.

What Manchester healthtech investors check

Regulatory status and NHS pathway come first. CE or UKCA marking for a device, MHRA registration where relevant, and a named NHS partner are the gates.

Then come the metrics. Patient outcomes, adoption rates, and cost-per-treatment comparisons matter more than general SaaS revenue in healthtech.

Use Ellty to share your clinical validation documents and financial model securely. Set permissions so investors see the outcomes data without downloading raw trial files.

How to approach university spinout funds in Manchester

Northern Gritstone and Parkwalk both require IP to sit cleanly with the company, not the university. Get your licence agreement signed before any investor conversation.

Then bring your clinical data from the lab. A proof-of-concept in human tissue or a real-world clinical setting is what separates a spinout from a research project.

Read Manchester AI investors if your healthtech product includes an AI diagnostic or ML clinical workflow component.